期刊文献+

罗格列酮对原发性高血压伴胰岛素抵抗患者的降血压作用 被引量:2

Effect of rosiglitazone on blood pressure in primary hypertension with insuline resistance
暂未订购
导出
摘要 目的评价罗格列酮(降血糖药)对原发性高血压伴胰岛素抵抗患者的降压作用。方法筛选出超重或肥胖的非糖尿病原发性高血压伴胰岛素抵抗病人100例,均服雷米普利降压治疗,降血压效果仍不理想;随机分为治疗组与对照组各50例,2组原用的降压药不变,原生活方式不变,治疗组病人加服罗格列酮片每日1次8?,疗程16周。分别测定2组治疗16周前后24h动态血压、身高、体质量、空腹血糖、血胰岛素、糖负荷后2h血糖、血胰岛素。结果罗格列酮治疗后,与治疗前或对照组相比,平均收缩压和舒张压均显著降低(P<0.05),降压总有效率达94%,明显优于对照组(P<0.05);罗格列酮组无低血糖、肝功能损害出现。结论罗格列酮对胰岛素抵抗的原发性高血压者有良好的降压作用,且安全性较好。
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2007年第3期227-229,共3页 The Chinese Journal of Clinical Pharmacology
基金 温州市科学技术局科研基金资助项目(Y2005A158)
  • 相关文献

参考文献6

  • 1Raji A,Seely EW,Bekins SA,et al.Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients[J].Diabetes Care,2003 ;26:172-178.
  • 2Sony J,Knepper MA,Hu X,et al.Rosiglitazone activates renal sodium and water-reabsorptive pathways and lower blood pressure in normal rates[J].Pharmacol Exp Ther,2004 ;318:426 -433.
  • 3Ryan MJ,Didion SP,Mathur S,et al.PPAR(gamma) agonist rosiglitazone improves in hypertensive transgenic mice[J].Hypertension,2004; 43:661 -666.
  • 4李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量:2127
  • 5Haffer SM,Gonzale ZC,Mieteinen H,et al.A prospective analysis of the HOMA model.The mecico city diabetes study[J].Diabetes Care,1996; 19:1138-1141.
  • 6Maheux P,Jeppesen J,Sheu WH,et al.Additive effects of obsity:Hypertension and type 2 diabetes on insulin resistance[J].Hpertension,1994 ;24:695-698.

共引文献2126

同被引文献12

  • 1李红辉,刘恩波,谢群,丁殊节,何涛,李家富.罗格列酮与二甲双胍对2型糖尿病患者血压的影响[J].中国临床药理学与治疗学,2005,10(6):717-720. 被引量:4
  • 2郭洁文,廖惠芳,李丽明,谢婉君.罗格列酮增强胰岛素抵抗大鼠胰岛素敏感性作用[J].中国医院药学杂志,2007,27(1):33-36. 被引量:2
  • 3Hansen TK,Gall MA,Tamow L,et al.Mannose-binding lectin and mortalityin type 2 diabetes[J].Arch Int Med.2006;166(18):2007-2013.
  • 4Cheung YF,Ho MH,Ip WK.Modulating effects of mannose binding lectin genotype on arterial stiffness in children after Kawasaki disease[J].Pediatr Res,2004;56(4):591-596.
  • 5Douglas G. Johns, Zhaohui Ao, Marianne Eybye, et al. Rosiglitazone protects against ischemia/repeffusion-induced leukocyte adhesion in the zucker diabetic fatty rat[ J]. JPET,2005 ;315 ( 3 ) : 1020-7.
  • 6Chen L,Sai Ma,Wei LX,et al. Cardioprotective and antiarrhythmic effect of U50,488H in ischemia/reperfusion rat heart [ J ]. Heart vessel ,2007; 22:335-44.
  • 7Gao F, Yue TL, Shi DW,et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation [J]. Cadiovasc Res, 2002 ; 53 : 414-22.
  • 8Walker M J, Curtis M J, Hearse D J, et al. The Lambeth Conventions guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion [ J]. Cardiovasc Res, 1988 ;22:447-55.
  • 9Abbott RD, Donnhue RP, Kannel WB,et al. The impact of diabetes on survival following myocardial infarction in men vswomen:the Framingham study[ J]. JAMA ,1988 ;260:3456-60.
  • 10Joosen AM, Bakker AH,Kersten S,et al. The PPARgamma ligand rosiglitazone influences triacylglycerol metabolism in non-obese males, without increasing the transcriptional activity of PPARgamma in the subcutaneous adipose tissue [ J]. Br J Nutr,2008 ;99 (3) :487-93.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部